SecBot SecBot
PRESS-RELEASE ·Filed Mar 12, 2026

IFRX

InflaRx N.V.
NEUTRAL
Impact 3/10
Horizondays Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Traders should await the actual earnings release on March 19, 2026. The absence of a conference call may limit near-term catalysts for volatility. Monitor for any pre-announcement signals or insider activity ahead of the release.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
IFRX ▲ +87.56% at T+60d
NEUTRAL call +87.56% · α vs SPY +76.87% · entry $0.9810 → $1.84
Entry = T+0 close
Mar 12, 2026
via day close
T+1d
-3.57%
call -3.57% · α -2.97%
$0.9460
settled 8mo ago
T+5d
-7.24%
call -7.24% · α -6.26%
$0.9100
settled 7mo ago
T+20d
+1.94%
call +1.94% · α -0.04%
$1.00
settled 7mo ago
T+60d
+87.56%
call +87.56% · α +76.87%
$1.84
settled 5mo ago

Price Chart

Loading chart...

Executive Summary

InflaRx N.V. announced it will release its Q4 and full-year 2025 financial and operating results on March 19, 2026, before market open. No conference call is planned. The press release contains no actual financial results or guidance.

Key Facts

  • InflaRx will release Q4 and full-year 2025 results on March 19, 2026, before market open.
  • No earnings conference call is scheduled.
  • No financial data, results, or guidance were disclosed in this announcement.
  • The company is advancing izicopan and vilobelimab in inflammatory disease programs.

Financial Impact

No financial impact from this announcement — results not yet released.

Risk Factors

  • Lack of a conference call may reduce transparency and limit investor engagement.
  • Biotech earnings often carry high volatility; absence of management commentary could amplify uncertainty.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3254509
21 reports for IFRX
Performance horizon
50% Hit rate @ T+20 5 of 10 directional calls Went positive at some point 7 of 10 best @ T+20▲ +142.72%Apr 9, 2026
Filters
Rows
Reports for IFRX — sortable, filterable
TypeNow
Oct 22, 2026
4d ago
6-K
NEUTRAL ★ 3/10
$1.56awaiting T+20—$1.58 (+0.96%)
Oct 22, 2026
4d ago
Press Release
NEUTRAL ★ 3/10
$1.53awaiting T+20—$1.58 (+2.94%)
Oct 2, 2026
24d ago
Press Release
NEUTRAL ★ 3/10
$1.72awaiting T+20—$1.58 (−8.43%)
Oct 1, 2026
25d ago
Press Release
NEUTRAL ★ 2/10
$1.71awaiting T+20—$1.58 (−7.89%)
Aug 14, 2026
10w ago
424B5
BEARISH ★ 5/10
$2.07 $2.02▲ +2.42%▲ +0.44%$1.58 (+23.91%)
Aug 13, 2026
10w ago
EFFECT
BEARISH ★ 5/10
$2.01 $2.09▼ −3.98%▼ −5.73%$1.58 (+21.64%)
Aug 6, 2026
11w ago
6-K
NEUTRAL ★ 5/10
$1.72 $2.23▲ +29.65%▲ +29.05%$1.58 (−8.43%)
Jun 30, 2026
16w ago
6-K
BULLISH ★ 6/10
$2.33 $1.65▼ −29.18%▼ −27.00%$1.58 (−32.40%)
Jun 30, 2026
16w ago
Press Release
BULLISH ★ 7/10
$2.24 $1.70▼ −24.11%▼ −23.08%$1.58 (−29.69%)
May 6, 2026
24w ago
424B5
BEARISH ★ 5/10
$2.65 $2.06▲ +22.26%▲ +25.40%$1.58 (+40.57%)
Showing 10 of 21

US Market Status

Market Closed — Opens Wed (11h 57m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 12, 2026